A Comparison of Sertraline-Reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.

NCT00636246

Last updated date
Study Location
Pfizer Investigational Site
Viljandi, Viljandi mk., 71024, Estonia
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Major Depressive Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects must fulfill the criteria for MDD without psychotic features as defined by DSMIV, based on clinical assessment and confirmed by Structural Clinical Interview for DSM-IV Axis I Disorder-Clinical Version (SCID-I) plus the MDD Specifiers included in the Research Version of SCID-I.

- HAM-D (17-item) ≥ 22 at Screening (Visit 1) and > 20 at Baseline (Visit 2).

- Minimum CGI-S ≥ 4 at Screening (Visit 1) and at Baseline (Visit 2).

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Known failure to satisfactory respond after adequate dose and duration (12 weeks) of
treatment with clomipramine and one SSRI, or with two or more SSRIs.


- Subjects with > 20% HAM-D (17-item) improvement (decrease) from Screening (Visit 1) at
Baseline (Visit 2).


- Subjects with uncorrected hypothyroidism or hyperthyroidism.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Major Depressive DisorderA Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression NCT00644982
  1. Cairns, Queensland
  2. Everton Park, Queensland
  3. North Cairns, Queensland
  4. Box Hill, Victoria
  5. Heidelberg, Victoria
  6. West Heidelberg, Victoria
  7. West Perth, Western Australia
  8. Adana,
  9. Ankara,
  10. Diyarbakir,
  11. Istanbul,
  12. Izmir,
  13. Izmit,
  14. Malatya,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderStudy Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder NCT00384033
  1. Beverly Hills, California
  2. Burbank, California
  3. Encino, California
  4. Los Alamitos, California
  5. Newport Beach, California
  6. Northridge, California
  7. Orange, California
  8. Pasadena, California
  9. Upland, California
  10. South Miami, Florida
  11. St. Petersburg, Florida
  12. Edwardsville, Illinois
  13. Farmington Hills, Michigan
  14. Flint, Michigan
  15. Okemos, Michigan
  16. Clementon, New Jersey
  17. Dayton, Ohio
  18. Portland, Oregon
  19. Philadelphia, Pennsylvania
  20. Salt Lake City, Utah
  21. Seattle, Washington
  22. Brown Deer, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderRelapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder NCT00887224
  1. Beverly Hills, California
  2. Encino, California
  3. Los Alamitos, California
  4. Orange, California
  5. Upland, California
  6. Aurora, Colorado
  7. Jacksonville, Florida
  8. South Miami, Florida
  9. St. Petersburg, Florida
  10. St. Petersburg, Florida
  11. Atlanta, Georgia
  12. Smyrna, Georgia
  13. Hoffman Estates, Illinois
  14. Rockville, Maryland
  15. New York, New York
  16. New York, New York
  17. Rochester, New York
  18. Dayton, Ohio
  19. Portland, Oregon
  20. San Antonio, Texas
  21. Seattle, Washington
  22. Edmonton, Alberta
  23. Medicine Hat, Alberta
  24. Kelowna, British Columbia
  25. Vancouver, British Columbia
  26. Bathurst, New Brunswick
  27. Burlington, Ontario
  28. Ottawa, Ontario
  29. Toronto, Ontario
  30. Gatineau, Quebec
  31. Pointe-Claire, Quebec
  32. Sherbrooke, Quebec
  33. Santiago,
  34. Santiago,
  35. Santiago,
  36. Medellin, Antioquia
  37. Barranquilla, Atlantico
  38. Bogota, Cundinamarca
  39. Bucamaranga, Santander
  40. Rijeka,
  41. Zagreb,
  42. Tallinn,
  43. Tallinn,
  44. Tartu,
  45. Voru,
  46. Vöru,
  47. Espoo,
  48. Helsinki,
  49. Joensuu,
  50. Kuopio,
  51. Seinajoki,
  52. Tampere,
  53. Turku,
  54. Caen,
  55. Dole,
  56. Douai,
  57. Orvault,
  58. Rennes,
  59. Liepaja,
  60. Sigulda,
  61. Sigulda,
  62. Strenci,
  63. Kaunas,
  64. Kaunas,
  65. Vilius,
  66. Vilnius,
  67. Vilnius,
  68. Vilnius,
  69. Skorzewo, Poznan
  70. Szczecin,
  71. Torun,
  72. Tuszyn,
  73. Wroclaw,
  74. Zuromin,
  75. Craiova, Dolj
  76. Brasov,
  77. Bucharest,
  78. Bucuresti,
  79. Bucuresti,
  80. Cluj Napoca,
  81. Bojnice,
  82. Bratislava,
  83. Liptovsky Mikulas,
  84. Michalovce,
  85. Rimavska Sobota,
  86. Trencin,
  87. Cape Town, Western Cape
  88. Durban,
  89. Paarl,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderStudy Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD) NCT01056289
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Comparison of Sertraline-Reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.
Official Title  ICMJE Sertraline/[S,S]-Reboxetine Combination Versus Sertraline And [S,S]-Reboxetine Monotherapy In Major Depressive Disorder (MDD) In A Double-Blind, Placebo-Controlled, Eight Week Study.
Brief Summary This study was designed to determine if the novel combination of the SSRI, sertraline, and the NRI reboxetine will increase antidepressant efficacy without sacrificing the favorable safety profile of SSRIs.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Depressive Disorder, Major
Intervention  ICMJE
  • Drug: sertraline/[S,S]-reboxetine
    Tablets, 50mg sertraline/2mg [S,S]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/4mg [S,S]-reboxetine for 5 and one half weeks.
  • Drug: sertraline/[S,S]-reboxetine
    Tablets, 50mg sertraline/2mg [S,S]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/6mg [S,S]-reboxetine for 5 and one half weeks.
  • Drug: sertraline
    Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks.
  • Drug: sertraline
    Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks
  • Drug: sertraline/[S,S]-reboxetine
    Tablets, 50mg sertraline/2mg [S,S]-reboxetine for 3 days orally, followed by 100mg sertraline/2mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg [S,S]-reboxetine for 5 and one half weeks.
  • Drug: Placebo
    Tablets, orally once per day for 8 weeks
  • Drug: sertraline/[S,S]-reboxetine
    Tablets, 50mg sertraline/2mg [S,S]-reboxetine orally for 3 days, followed by 100mg sertraline/2mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg [S,S]-reboxetine for 5 and one half weeks
  • Drug: [S,S]-reboxetine monotherapy
    Tablets, 2 mg/day orally for 3 days, followed by 4 mg/day orally for 4 and one half weeks, followed by 6mg/day for 3 weeks
Study Arms  ICMJE
  • Experimental: Sertraline/[S,S]-Reboxetine-satellite150/4
    Intervention: Drug: sertraline/[S,S]-reboxetine
  • Experimental: Sertraline/[S,S]-Reboxetine-satellite150/6
    Intervention: Drug: sertraline/[S,S]-reboxetine
  • Active Comparator: sertraline-satellite
    Intervention: Drug: sertraline
  • Active Comparator: sertraline-main
    Intervention: Drug: sertraline
  • Experimental: Sertraline/[S,S]-Reboxetine-satellite150/2
    Intervention: Drug: sertraline/[S,S]-reboxetine
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Experimental: Sertraline/[S,S]-Reboxetine-main
    Intervention: Drug: sertraline/[S,S]-reboxetine
  • Active Comparator: [S,S]-reboxetine-main
    Intervention: Drug: [S,S]-reboxetine monotherapy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 7, 2008)
510
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE August 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects must fulfill the criteria for MDD without psychotic features as defined by DSMIV, based on clinical assessment and confirmed by Structural Clinical Interview for DSM-IV Axis I Disorder-Clinical Version (SCID-I) plus the MDD Specifiers included in the Research Version of SCID-I.
  • HAM-D (17-item) ? 22 at Screening (Visit 1) and > 20 at Baseline (Visit 2).
  • Minimum CGI-S ? 4 at Screening (Visit 1) and at Baseline (Visit 2).

Exclusion Criteria:

  • Known failure to satisfactory respond after adequate dose and duration (12 weeks) of treatment with clomipramine and one SSRI, or with two or more SSRIs.
  • Subjects with > 20% HAM-D (17-item) improvement (decrease) from Screening (Visit 1) at Baseline (Visit 2).
  • Subjects with uncorrected hypothyroidism or hyperthyroidism.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Estonia,   Russian Federation
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00636246
Other Study ID Numbers  ICMJE A0501075
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP